## 1 Exploring WNT2 Polymorphisms in Comitant Strabismus: A Genetic Association Study

- 2 Zainab Zehra,<sup>1</sup> Christopher S. von Bartheld,<sup>2</sup> Andrea B. Agarwal,<sup>2</sup> Hans Vasquez-Gross,<sup>3</sup> Sorath
- 3 Noorani Siddiqui,<sup>4</sup> Maleeha Azam,<sup>1,§</sup> Raheel Qamar<sup>5,6,§</sup>
- 4
- <sup>5</sup> <sup>1</sup>Translational Genomics Laboratory, Department of Biosciences, COMSATS University
- 6 Islamabad, Pakistan;
- <sup>7</sup><sup>2</sup>Department of Physiology and Cell Biology, University of Nevada, Reno School of Medicine,
- 8 Reno, NV, USA;
- 9 <sup>3</sup>Nevada Bioinformatics Center, RRID: SCR\_017802, University of Nevada, Reno;
- <sup>4</sup>Al-Shifa Eye Trust Hospital, Rawalpindi, Pakistan;
- <sup>5</sup>Pakistan Academy of Sciences, Islamabad, Pakistan;
- <sup>6</sup>Science and Technology Sector, ICESCO, Rabat, Kingdom of Morocco
- 13
- 14
- 15 Shared correspondence
- 16 § <u>Address for correspondence</u>
- 17 Raheel Qamar, Head of Science and Technology Sector, ICESCO, Rabat, Morocco. Phone:
- 18 (212)-(537 56 60 52); Email: raheelqamar@hotmail.com
- 19 Maleeha Azam, Translational Genomics Laboratory, Department of Biosciences, COMSATS
- 20 University Islamabad, Pakistan, Tarlai Kalan, Park Road, Islamabad-45600, Pakistan. Phone:
- 21 (92)-(51)-9235033; Fax: (92)-(51)-9247008; Email: malihazam@gmail.com

## 22 Abstract

Background: Strabismus is a complex oculomotor condition characterized by a misalignment of the visual axis. The genetics of strabismus are poorly defined although a few candidate genes have been identified, among which is the WNT2 gene. Our study was designed to assess the association of single nucleotide polymorphisms (SNPs) of *WNT2* in Pakistani strabismus patients.

Methods: A total of six SNPs, three intronic and three in the 3' untranslated region, were screened in the current study. Logistic regression was performed using a dominant, recessive and additive model to determine the association of SNPs with strabismus and its clinical subtypes: esotropia and exotropia. Furthermore, haplotype analysis was performed.

Results: Regression analysis revealed an association of rs2896218, rs3779550, rs2285544 and 32 rs4730775 with strabismus under the dominant model. When analyzed separately, rs2896218 and 33 rs2285544 were found to be associated with both esotropia and exotropia, while rs4730775 was 34 significantly associated only with exotropia under the dominant model. Based on clinical 35 parameters, rs2896218, rs2285544 and rs4730775 were also found to be associated with the 36 group of strabismus patients who were diagnosed at birth, but not in the group of patients who 37 were diagnosed later in life. Haplotype analysis revealed that the haplotype A T T 38 (corresponding to rs2896218, rs3779550 and rs2285544) was significantly more prevalent in the 39 strabismus group. 40

41 Conclusion: Overall, the results of the present study suggests an association of *WNT2*42 polymorphisms with strabismus and its subtypes in the Pakistani population, though further
43 studies are needed to elucidate their role in strabismus etiology.

2

44	What is already known on this topic
45	• Strabismus is a common oculomotor condition with a genetic component.
46	• <i>WNT2</i> has been identified as a candidate gene for comitant strabismus.
47	What this study adds
48	• Two WNT2 polymorphisms not previously reported have been found to be associated
49	with strabismus.
50	• There are genetic variations between clinical subtypes of strabismus (esotropia and
51	exotropia).
52	• WNT2 polymorphisms are associated with age at the time of diagnosis and family history
53	• Combinations of different alleles (haplotypes) are associated with the disease.
54	How this study might affect research, practice or policy
55	• Our study adds to the limited genetic data for strabismus and suggests further studies or
56	the role of <i>WNT2</i> in strabismus causation.

# 57 Introduction

58 Strabismus is a common ocular disorder with a worldwide prevalence of 2-3%. The prevalence 59 of horizontal subtypes of strabismus, esotropia and exotropia, vary in different parts of the world 60 and can be influenced by several risk factors such as ethnicity,<sup>1</sup> seasonality of birth,<sup>2</sup> gestational 61 age and birth weight, paternal age, and family history.<sup>3</sup>

Comitant strabismus (CS), where the degree of misalignment remains constant regardless of the 62 direction of gaze, accounts for more than 95% of all strabismus cases. Despite being fairly 63 64 common, the mechanisms underlying its onset are poorly understood. Genetics and a positive family history have been implicated in playing a significant role in the disease. Recent studies 65 have aimed to identify genetic variants responsible for disease causation. In 2018, a genome 66 wide association study (GWAS) by Shabaan et al., (2018)<sup>4</sup> identified a significant association of 67 rs2244352 in intron 1 of the WRB with non-accommodative esotropia in an American population 68 of European ancestry. Two studies identified LRP2 and FOXG1 as potential candidate genes for 69 strabismus,<sup>5,6</sup> while another study suggested MGST2 and WNT2 as potential candidate genes for 70 strabismus in a Japanese population.<sup>7</sup> 71

72 WNT2 is a member of the WNT family of genes, which encode several secreted signaling proteins. These genes play an important role in early development such as neural development 73 and patterning during embryogenesis,<sup>8</sup> including early development of ocular tissues.<sup>9</sup> WNTs are 74 also involved in embryonic muscle development by regulating the activity of myogenic 75 regulatory factors.<sup>10</sup> WNT2 plays a role in the activation of the canonical WNT signalling 76 pathway by acting as a ligand for Frizzled receptors.<sup>11</sup> WNT2 can also initiate differentiation of 77 embryonic stem cells via a non-canonical WNT signalling pathway<sup>12</sup> and may also be involved 78 in the development of embryonic brains.<sup>13</sup> 79

WNT2 is located on chromosome 7 (7q31.2), which has previously been identified as a susceptibility locus for CS.<sup>14</sup> The same group later identified WNT2 as a candidate gene for CS at this locus. Being an important signalling molecule, together with being a candidate gene for CS, we therefore explored potential roles of the WNT2 gene by screening its previously reported polymorphisms in a cohort of strabismus patients. The aim of the present study was to investigate whether single nucleotide polymorphisms (SNPs) in WNT2 are associated with strabismus or its clinical subtypes.

#### 87 Methods

#### 88 Ethical Review and Cohort Recruitment

Our project was approved by the Ethics Review Board, Department of Biosciences, COMSATS
University Islamabad (CUI-Reg/Notif-452/20/526) and conforms to the tenets of the Declaration
of Helsinki. All participants and/or accompanying guardians were briefed about the purpose of
the study and written consent was obtained prior to sample collection.

93 Strabismus patients were recruited from the Al-Shifa Trust Eye Hospital, Rawalpindi after 94 diagnosis by an experienced ophthalmologist, which included cover test, prism cover test and 95 Hirschberg test. All participants were briefed about the study before their clinical data were 96 collected. Complete data of all the participants was not available as they or their accompanying 97 guardians had limited information such as, about other strabismus cases in the family or age of 98 the patient at first diagnosis.

# 99 Inclusion/Exclusion Criteria

Patients diagnosed with CS were included in the study regardless of age, gender, or ethnic background. Patients having a history of any other ocular disorder, ocular surgery, trauma or injury to the eye, or any neurological condition were excluded from the study. Patients suffering from phoria, vertical strabismus, paralytic strabismus, and amblyopia-induced strabismus were also excluded. Age-matched healthy controls were recruited from local schools and universities including students and staff.

#### **106 Sample Collection and DNA Extraction**

A total of 5mL blood was collected from each individual in EDTA tubes and stored at 4°C prior
to use. Genomic DNA was isolated from the whole blood using the organic phenol/chloroform
method as described by Sambrook and Russel (2001)<sup>15</sup> with minor modifications.

## 110 Gene and SNP Selection

Previous genetic linkage studies have identified the 7q31.2 gene locus<sup>14</sup> and WNT2 gene<sup>7</sup> as a candidate for strabismus. In our study, we screened a total of six WNT2 polymorphisms: rs2896218 (NC\_000007.14:g.117279924G>A), rs3779550 (NC\_000007.14:g.117287306C>T), rs2285544 (NC 000007.14:g.117304229T>A), rs4730775 (NC 000007.14:g.117277064C>T),

115 rs3840660 (NC 000007.14:g.117277191 117277192insA) and rs2024233 (NC 000007.14:g.117277373G>A) in strabismus patients and healthy controls. The SNPs 116 rs2896218, rs2285544 and rs3779550 are intronic variants, while rs4730775, rs3840660 and 117 rs2024233 are present in the 3' untranslated region (3' UTR). Three of these variants, rs2896218, 118 rs2285544 and rs2024233 were previously found to be associated with strabismus,<sup>7</sup> however, the 119 results were not stratified based on clinical subtypes, esotropia and exotropia. Thus, we screened 120 121 WNT2 polymorphisms in the Pakistani cohort to ascertain their association with strabismus as well as with its clinical subtypes. 122

## 123 Genotyping

124 To screen the selected variants, two methods were employed. Tetra-primer amplification 125 refractory mutation system-polymerase chain reaction (tetra-ARMS-PCR) technique was used for the genotyping of SNPs, rs2896218, rs3779550 and rs2285544. Primers were designed 126 following the protocol as described by Medrano & de Oliveira (2014)<sup>16</sup> (Supplementary Table 127 1). About 5% of the samples for each genotype were repeated for cross-verification of the 128 genotyping results. For the other three SNPs, rs4730775, rs3840660 and rs2024233, which were 129 within 500 bp, the Sanger sequencing method was used for genotyping. A total of 66 control and 130 106 strabismus cases (53 esotropic and 53 exotropic) were sequenced to genotype these three 131 polymorphisms. The sequencing was carried out by the Nevada Genomics Center at the 132 University of Nevada, Reno (https://www.unr.edu/genomics) and the results were viewed using 133 SnapGene Viewer (v.6.2.2). All PCR reactions were done using O5<sup>®</sup> Hot Start High-Fidelity 2X 134 Master Mix (New England Biolabs, Inc.). The PCR products were separated on standard agarose 135 gels (2%) in TAE buffer and visualized on a Bio-Rad Gel Doc XR system. 136

#### 137 Statistical Analysis

Hardy Weinberg Equilibrium (HWE) test and Principal Component Analysis (PCA) were performed to test for the population structure of the cohort. Linkage Disequilibrium (LD) was computed to detect the possible linkage between the studied SNPs. Logistic regression analysis under additive, dominant and recessive genetic models was applied where all the SNPs were tested for strabismus (strabismus vs. control), esotropia (esotropia vs. control) and exotropia (exotropia vs. control). In addition, analysis was done after dividing the strabismus group into subgroups based on demographic characteristics including age at diagnosis, family history of

strabismus, consanguinity among parents, and exposure to passive smoking. All tests were 145 computed using R statistical software (v.4.2.0).<sup>17</sup> Haplotypes were generated from the obtained 146 genotypes using Beagle (beagle.08Feb22.fa4.jar). An online 147 tool (https://statpages.info/ctab2x2.html) was used to calculate the odds ratios, 95% confidence 148 interval and p-values between strabismus and controls for each haplotype combination. 149

#### 150 **Results**

#### 151 Cohort overview

A total of 315 strabismic patients (141 esotropic and 162 exotropic) and 230 controls were included in this study. In the strabismus group, 52.9% were males, while in the controls 64.3% were males. The mean age of subjects in the strabismus and control groups was 16.4 and 28.2 years, respectively. Out of the total strabismus cohort 52.1% were diagnosed at birth, 50.9% had a positive family history of strabismus, and 67.1% subjects reported consanguinity among parents (Supplementary Table 2).

#### 158 Hardy Weinberg Equilibrium (HWE) and Principal Component Analysis (PCA)

159 Among the studied variants, only rs4730775, rs3840660 and rs2024233 were found to be in HWE with a p-value of 0.21, 0.76 and 0.54, respectively. However, the genotype frequencies of 160 161 variants rs2896218, rs3779550 and rs2285544 did not match those expected from the HWE (pvalue=< 0.00001). The result from PCA revealed no stratification of the control group in the 162 present cohort with 1000 Genomes data; although, a separate cluster was seen for the strabismus 163 group (Supplementary Figure 1). However, the minor allele frequencies (MAF) of rs2896218, 164 rs3779550 and rs2024233 in the present control group were significantly different from that 165 reported for MAF in the Punjabi cohort from Lahore, Pakistan (PJL) dataset (Supplementary 166 Table 3). 167

#### 168 Linkage Disequilibrium Analysis

Linkage disequilibrium analysis in the control group of the studied cohort revealed linkage between rs2896218, rs3779550 and rs2285544. In addition, the SNPs rs4730775 and rs3840660 were found to be linked, while rs3840660 and rs2024233 were in linkage disequilibrium (Supplementary Table 4).

#### 173 Association of WNT2 polymorphisms with strabismus

- 174 Logistic regression analysis under the dominant model showed significant protective association
- 175 of rs2896218 [Odds Ratio (OR)=0.75 (95% Confidence Interval (CI)=0.66 0.86), p-
- 176 value=5.08e-05] and rs2285544 [OR=0.89 (95% CI=0.81 0.97), p-value=0.01], while there was
- 177 significant risk association of rs3779550 [OR=1.17 (95% CI=1.00 1.36), p-value= 0.04] and

178 rs4730775 [OR=1.15 (95% CI=1.00- 1.33), p-value=0.05] (Table 1).

- 179 When adjusted for age and gender, rs2896218 [OR=0.79 (95% CI=0.70 0.89), p-value=
- 180 0.00017], rs2285544 [OR=0.92 (95% CI=0.85 0.99), p-value=0.05] and rs4730775 [OR=1.13
- 181 (95% CI=1.00 1.27), p-value=0.05] retained their significance.
- The variant rs4730775 also showed risk association with strabismus under the additive model [OR=1.10 (95% CI=1.00- 1.21), p-value=0.05]. However, no association was observed for any of the SNBs under the recessive model
- 184 of the SNPs under the recessive model.

#### 185 Association of WNT2 polymorphisms with strabismus subtypes

When strabismus subtypes were separately analyzed, a significant protective association was found for rs2896218 and rs2285544 with both esotropia and exotropia under the dominant model. However, rs4730775 showed significant risk association only with exotropia [OR=1.19 (95% CI=1.00 - 1.43), p-value=0.05], which was further strengthened after adjusting for age and gender [OR=1.22 (95% CI=1.04 - 1.42), p-value=0.01]. The variant rs3840660 also showed significant risk association with exotropia under dominant model but only after adjusting for age and gender [OR=1.18 (95% CI=1.01 - 1.38), p-value=0.04] (Table 1).

- Under the additive model, rs2896218 [OR=0.88 (95% CI)=0.80 0.98), p-value= 0.01] and rs2285544 [OR=0.90 (95% CI0.81 - 0.99), p-value= 0.04] showed protective association with esotropia, while rs4730775 [OR=1.14 (95% CI=1.01 - 1.28), p-value= 0.03] and rs3840660 [OR=1.14 (95% CI=1.00 - 1.28), p-value=0.04] were found to be risk associated with exotropia.
- 197 No association was found between rs2024233 and strabismus or any of its subtypes (Table 1).

### 198 Association of WNT2 polymorphisms with strabismus based on demographic features

199 To determine whether the demographic risk factors influenced the association of the studied 200 variants, we stratified the strabismus group based on the age at diagnosis, family history, parental

consanguinity and exposure to smoke. The results revealed significant protective association of
rs2896218 and rs2285544, and risk association of rs4730775 with strabismus patients diagnosed
at birth while no association was observed for any variant with strabismus patients diagnosed
later in life (Table 2).

205 It was also observed that rs2896218 and rs2285544 showed significant protective association, while rs3840660 showed risk association with strabismus patients with a positive family history. 206 The SNP rs3779550 showed protective association with patients with no family history (Table 207 3). Based on consanguinity, rs2896218 and rs3779550 showed an overall risk association with 208 209 strabismus from non-consanguineous families. However, rs3840660 showed risk association and rs2024233 showed protective association with esotropia in strabismus in consanguineous parents 210 (Table 4). Similarly, no association was observed between the studied variants and strabismus 211 with a positive smoking exposure status. However, rs2285544 showed protective association 212 with overall strabismus with no smoking exposure (Table 5). 213

#### 214 Haplotype Analysis

Haplotype analysis was conducted from the obtained genotype data for rs2896218, rs3779550 215 and rs2285544, to see whether any haplotype combination was associated with strabismus. A 216 total of eight haplotype combinations were obtained with one being a rare haplotype (total 217 frequency = 0.007). It was found that the haplotype A T T (corresponding to rs2896218, 218 rs3779550 and rs2285544, respectively), was significantly more prevalent in the strabismus 219 group with a p-value=0.001 (Table 6). Another haplotype, A T A, was more prevalent in the 220 control group (p-value=0.006). In addition to these, two other haplotypes, G C A and A C A 221 tended to be associated with strabismus and control groups, respectively (p-values=0.05). 222

## 223 Discussion

Comitant strabismus (CS) is a common condition comprising more than 95% of all strabismus cases. Recent studies have identified candidate genes associated with CS, including *LRP2*, *WRB*, *MGST2*, *WNT*, *FOXG1* and *IGF1*.<sup>4–7,18</sup> The *WNT2* gene is located at the 7q31.2 locus, which has been previously identified as a susceptibility locus for CS including both of its subtypes, esotropia and exotropia.<sup>14,19</sup> Later, another study revealed association of *WNT2* polymorphisms, rs2896218, rs2285544 and rs2024233, with strabismus in a Japanese cohort.<sup>7</sup> However, their

results were not stratified based on esotropia and exotropia. In the current study we screened six
SNPs of *WNT2* in strabismus patients of Pakistani origin, out of which four were found to be
associated with strabismus and one of its subtypes.

Our results revealed a significant protective association of rs2896218 and rs2285544 with esotropia, while disease association was observed for rs4730775 and rs3840660 with exotropia. However, rs2024233 was not associated with any strabismus subtype.

236 The polymorphism rs4730775 has previously been implicated in fibrosis of musculoskeletal tissues in diseases such as Dupuytren's disease.<sup>20,21</sup> Fibrosis of extraocular muscles (EOMs) has 237 also been observed in incomitant forms of strabismus.<sup>22</sup> While the specific role of WNT2 in 238 fibrosis of the EOM is not well-established, it is known that the WNT signalling pathway is 239 240 involved in the regulation of tissue fibrosis in general. WNT signalling has also been implicated in the development of fibrotic conditions in various organs, including the lungs, liver, and 241 skin.<sup>23–25</sup> Dysregulation of WNT signalling can contribute to the activation of fibroblasts, the 242 243 production of excessive extracellular matrix (ECM) proteins (collagens), and the development of fibrosis.<sup>26</sup> Moreover, the ECM stiffness impacts the expression of genes involved in the Wnt/β-244 catenin pathway, thus resulting in a positive feedback loop.<sup>27</sup> We have previously reported that 245 the expression of ECM-related genes, especially collagens, are altered in strabismic EOMs,<sup>28</sup> an 246 observation which was also reported by Agarwal et al., (2016)<sup>29</sup> and Altick et al., (2012).<sup>30</sup> ECM 247 also regulates the cell differentiation and mineralization of tissues during craniofacial 248 development.<sup>31</sup> Barreto et al. (2017)<sup>32</sup> has shown that stiffer substrates can accelerate bone 249 formation and suggested that ECM stiffness could lead to premature bone ossification in 250 craniosynostosis, a condition characterized by the premature fusion of bones of the skull thus 251 restricting brain growth and development. Aberrations in WNT signalling have also been 252 reported in craniosynostosis,<sup>33–35</sup> while WNT2 was found to be dysregulated in Apert syndrome, 253 a genetic condition characterized by fusion of the skull, hands, and feet bones.<sup>36</sup> Strabismus is 254 the most prevalent ocular abnormality in both non-syndromic and syndromic craniosynostosis, 255 including Apert and Crouzon syndromes.<sup>37</sup> It is possible that WNT2-induced differences in facial 256 and orbital anatomy may contribute to an altered frequency of strabismus and its subtypes. 257

The prevalence of strabismus is also increased in certain neurological conditions including autism spectrum disorder (ASD) compared to the general population.<sup>38</sup> A recent study has

implicated the involvement of *WNT2* polymorphisms with altered cortical thickness in patients with ASD.<sup>39</sup>Altered cortical thickness has also been reported in CS patients.<sup>40</sup> Thus, it is possible that errors in early development of the brain may cause strabismus, however further studies exploring brain development in CS are needed to establish the role of *WNT2* polymorphisms in strabismus causation.

A total of six polymorphisms were screened in the present study, out of which only three i.e., 265 rs4730775, rs3840660 and rs2024233 were found to be in HWE. The principle of HWE assumes 266 that there is no mutation, no selection, no gene flow, infinite population size and random mating. 267 Though the sample size for this study was appropriate (according to https://www.calculator.net/) 268 it could be one of the limiting factors in achieving HWE in the studied cohort. Moreover, 269 Pakistan has one of the highest rates of consanguineous marriages (https://www.consang.net/)<sup>41</sup> 270 and almost half of our samples have positive consanguinity, which could explain the deviation 271 from HWE, which is based on the premise of random mating. Some of the previous studies from 272 our research group also found that the studied variants did not adhere to the HWE,<sup>18,42</sup> which 273 could indicate inbreeding and population stratification. However, for the present study, the PCA 274 analysis showed no population stratification for the control cohort used. A study by Salanti et al., 275 (2005)<sup>43</sup> emphasized that the deviations from HWE in genetic association studies are quite 276 277 common and, in most cases, can be explained by low sample size. The same study cautioned that the lack of power in the study cohorts could also make it harder to detect the extent of inbreeding 278 279 and thus any deviation from HWE.

To further validate the protective association of rs2896218 and rs2285544, these variants were found to be benign in terms of disease probability (<u>https://regsnps-intron.ccbb.iupui.edu/</u>). However, the variant rs2285544 was predicted to activate a new cryptic acceptor splice site (<u>https://hsf.genomnis.com/home</u>). This, along with the results of haplotype analysis, further strengthens the possibility of a specific combination of variants and interactions among multiple genetic markers influencing the disease phenotype. Future genetic and proteomic studies on the *WNT2* gene may be helpful in exploring this idea further.

We compared allele frequencies of the studied control cohort to the PJL dataset from the 1000 Genomes project and found significant differences for three of the variants i.e., rs2896218, rs3779550 and rs2024233. Hashmi et al., (2022)<sup>44</sup> and Khan et al., (2020)<sup>42</sup> from our research

290 group reported similar observations, one reason for this could be that the majority of the samples collected for this and the previous studies were from the twin cities of Rawalpindi and 291 292 Islamabad. Both these cities comprise people from diverse backgrounds including a high influx of Pashtuns from Khyber Pakhtunkhwa. The PJL dataset consists of samples from Lahore, which 293 is approximately 400km distant from the twin cities and mostly contains Punjabi ethnic group. 294 The differences of the current cohort from the PJL dataset suggest that the population in the twin 295 cities is heterogenous as compared to the PJL reference dataset. Moreover, the variants screened 296 in the present study are in the non-coding region so their corresponding genotypes in the PJL 297 dataset are derived from low coverage whole genome sequencing data, which does not produce 298 high-quality genotypes.<sup>42</sup> The number of samples in the PJL dataset is also low as compared to 299 our control cohort, thus further underpowering their results. 300

301 The LD pattern obtained for the PJL dataset was compared to the LD calculated from the control cohort of the present study, which also indicated some differences. The controls collected for this 302 303 study were carefully selected to only include healthy individuals without a history of any ocular or systemic condition, but the same criteria could not be verified for the PJL dataset. Thus, the 304 305 observed differences could be a result of 'non-random' sampling of controls for the present study. The results of our PCA analysis show that the control group did not cluster separately 306 307 from the overall 1000 Genomes data, confirming that the current control group is a reliable representation of an overall unaffected population. However, we did observe a separate cluster 308 for the strabismus group indicating that this is indeed different from the overall 1000 Genomes 309 data. 310

The results of the present study suggest an involvement of WNT2 polymorphisms with 311 strabismus. Being an early developmental gene, it supports the idea that strabismus develops as a 312 313 result of abnormal muscle architecture and signaling defects during embryonic development. The fact that the association of the studied variants (rs2896218, rs2285544 and rs4730775) was only 314 observed in strabismus cases that were diagnosed at birth and not in the patient group diagnosed 315 later in life, strengthens this conjecture. In addition, the results of our haplotype analysis suggest 316 317 that the presence and combination of multiple variants may influence the severity of the condition. Nevertheless, many individuals develop strabismus later in life, indicating a 318 heterogenous nature of the disease. It is possible that different underlying mechanisms are at play 319

affecting different stages of muscle development and regeneration capacities or alterations in visual or motor pathways,<sup>45</sup> ultimately leading to a similar phenotype. Thus, there is a need for extensive genetic studies to further investigate how genetic variations influence strabismus. Moreover, familial studies using high throughput techniques and functional studies must be carried out to identify the genetic variants playing a major role in strabismus causation.

# 325 **References**

326 327 328	1.	Hashemi H, Pakzad R, Heydarian S, <i>et al.</i> Global and regional prevalence of strabismus: a comprehensive systematic review and meta-analysis. <i>Strabismus</i> 2019; <b>27</b> :54-65. doi:10.1080/09273972.2019.1604773
329 330 331 332	2.	Agarwal AB, Cassinelli K, Johnson LA, <i>et al.</i> Seasonality of births in horizontal strabismus: comparison with birth seasonality in schizophrenia and other disease conditions. <i>J Dev Orig Health Dis</i> 2019; <b>10</b> :636-644. doi:10.1017/S2040174419000102. Seasonality
333 334 335	3.	Maconachie GDE, Gottlob I, McLean RJ. Risk Factors and Genetics in Common Comitant Strabismus. <i>JAMA Ophthalmol</i> 2013; <b>131</b> :1179-1186. doi:10.1001/jamaophthalmol.2013.4001
336 337 338	4.	Shaaban S, Mackinnon S, Andrews C, <i>et al.</i> Genome-Wide Association Study Identifies a Susceptibility Locus for Comitant Esotropia and Suggests a Parent-of-Origin Effect. <i>Invest Ophthalmol Vis Sci</i> 2018; <b>59</b> :4054-4064. doi:10.1167/iovs.18-24082
339 340 341	5.	Wang Y, Chen X, Jiang T, <i>et al.</i> Expanding the phenotypic spectrum of mutations in LRP2 : a novel candidate gene of non-syndromic familial comitant strabismus. <i>J Transl Med</i> 2021; <b>19</b> :1-11. doi:10.1186/s12967-021-03155-z
342 343 344	6.	Ye X (Cynthia), Roslin NM, Paterson AD, <i>et al.</i> Linkage analysis identifies an isolated strabismus locus at 14q12 overlapping with FOXG1 syndrome region. <i>J Med Genet</i> 2022; <b>59</b> :46-55. doi:10.1136/jmedgenet-2020-107226
345 346	7.	Zhang J, Matsuo T. MGST2 and WNT2 are candidate genes for comitant strabismus susceptibility in Japanese patients. <i>PeerJ</i> 2017; <b>Oct 17</b> :e3935. doi:10.7717/peerj.3935
347 348 349	8.	Mulligan KA, Cheyette BNR. Wnt Signaling in Vertebrate Neural Development and Function. <i>J neuroimmune Pharmacol</i> 2012; <b>7</b> :774-787. doi:10.1007/s11481-012-9404-x.Wnt
350 351	9.	Fuhrmann S. Wnt signaling in eye organogenesis. <i>Organogenesis</i> 2008; <b>4</b> :60-67. doi:10.4161/org.4.2.5850

14

- 352 10. Cisternas P, Henriquez JP, Brandan E, Inestrosa NC. Wnt Signaling in Skeletal Muscle
- 353 Dynamics: Myogenesis, Neuromuscular Synapse and Fibrosis. *Mol Neurobiol*
- 354 2013;**49**:574–589. doi:10.1007/s12035-013-8540-5
- 11. Fedon Y, Bonnieu A, Gay S, Vernus B, Bacou F, Bernardi H. Role and Function of Wnts
- 356 in the Regulation of Myogenesis: When Wnt Meets Myostatin. In: Skeletal Muscle From
- 357 *Myogenesis to Clinical Relations*. InTech; 2012. doi:10.5772/48330
- Onizuka T, Yuasa S, Kusumoto D, *et al.* Wnt2 accelerates cardiac myocyte differentiation
  from ES-cell derived mesodermal cells via non-canonical pathway. *J Mol Cell Cardiol*2012;**52**:650-659. doi:10.1016/j.yjmcc.2011.11.010
- 361 13. Sousa KM, Villaescusa JC, Cajanek L, *et al.* Wnt2 Regulates Progenitor Proliferation in
  362 the Developing Ventral Midbrain. *J Biol Chem* 2010;**285**:7246-7253.
  363 doi:10.1074/jbc.M109.079822
- Shaaban S, Matsuo T, Fujiwara H, *et al.* Chromosomes 4q28.3 and 7q31.2 as New
  Susceptibility Loci for Comitant Strabismus. *Invest Ophthalmol Vis Sci* 2009;**50**:654-661.
  doi:10.1167/iovs.08-2437
- 367 15. Sambrook J, Russell DW. *Molecular Cloning: A Laboratory Manual*. Vol 1. 3rd ed. New
  368 York: Cold Spring Harbor Laboratory Press; 2001.
- Medrano RFV, de Oliveira CA. Guidelines for the Tetra-Primer ARMS–PCR Technique
  Development. *Mol Biotechnol* 2014;**56**:599-608. doi:10.1007/s12033-014-9734-4
- 17. R Core Team. R: A Language and Environment for Statistical Computing. 2022.
- 372 18. Zehra Z, Khan N, Nadeem M, *et al.* Association of IGF1 polymorphisms with exotropia in
  a Pakistani cohort. *Mol Vis* 2022;28:369-377.
- Fujiwara H, Matsuo T, Sato M, *et al.* Genome-wide search for strabismus susceptibility
  loci. *Acta Med Okayama* 2003;57:109-116.
- Dolmans GH, Werker PM, Hennies HC, *et al.* Wnt Signaling and Dupuytren's Disease. N
   *Engl J Med* 2011;365:307-317. doi:10.1056/NEJMoa1101029
- 378 21. Anderson ER, Ye Z, Caldwell MD, Burmester JK. SNPs Previously Associated with

379	Dupuytren's Disease Replicated in a North American Cohort. Clin Med Res 2014;12:133-
380	137. doi:10.3121/cmr.2013.1199

- Wang SM, Zwaan J, Mullaney PB, *et al.* Congenital fibrosis of the extraocular muscles
  type 2, an inherited exotropic strabismus fixus, maps to distal 11q13. *Am J Hum Genet*1998;63:517-525. doi:10.1086/301980
- Baarsma HA, Königshoff M. 'WNT-er is coming': WNT signalling in chronic lung
  diseases. *Thorax* 2017;**72**:746-759. doi:10.1136/thoraxjnl-2016-209753
- Nishikawa K, Osawa Y, Kimura K. Wnt/β-Catenin Signaling as a Potential Target for the
  Treatment of Liver Cirrhosis Using Antifibrotic Drugs. *Int J Mol Sci* 2018;19:3103.
  doi:10.3390/ijms19103103
- 389 25. Griffin MF, Huber J, Evan FJ, Quarto N, Longaker MT. The role of Wnt signaling in skin
  390 fibrosis. *Med Res Rev* 2022;42:615-628. doi:10.1002/med.21853
- 26. Działo E, Czepiel M, Tkacz K, Siedlar M, Kania G, Błyszczuk P. WNT/β-Catenin
  Signaling Promotes TGF-β-Mediated Activation of Human Cardiac Fibroblasts by
  Enhancing IL-11 Production. *Int J Mol Sci* 2021;22:10072. doi:10.3390/ijms221810072
- Du J, Zu Y, Li J, *et al.* Extracellular matrix stiffness dictates Wnt expression through
  integrin pathway. *Sci Rep* 2016;6:20395. doi:10.1038/srep20395
- Zehra Z, von Bartheld CS, Azam M, Qamar R. Expression profiling of extracellular
  matrix related genes in patients with strabismus. *Clin Experiment Ophthalmol*2023;51:646-649. doi:10.1111/ceo.14242
- Agarwal AB, Feng CY, Altick AL, *et al.* Altered protein composition and gene expression
  in strabismic human extraocular muscles and tendons. *Investig Ophthalmol Vis Sci*2016;57:5576-5585. doi:10.1167/iovs.16-20294
- 402 30. Altick AL, Feng C, Schlauch K, Johnson LA, von Bartheld CS. Differences in Gene
  403 Expression between Strabismic and Normal Human Extraocular Muscles. *Invest*404 *Ophthalmol Vis Sci* 2012;**53**:5168-5177. doi:10.1167/iovs.12-9785
- 405 31. Cruz Walma DA, Yamada KM. Extracellular Matrix in Human Craniofacial

406		Development. J Dent Res 2022;101:495-504. doi:10.1177/00220345211052982
407 408 409	32.	Barreto S, González-Vázquez A, R. Cameron A, O'Brien FJ, Murray DJ. Identification of stiffness-induced signalling mechanisms in cells from patent and fused sutures associated with craniosynostosis. <i>Sci Rep</i> 2017; <b>7</b> :11494. doi:10.1038/s41598-017-11801-0
410 411 412	33.	Behr B, Longaker MT, Quarto N. Differential activation of canonical Wnt signaling determines cranial sutures fate: A novel mechanism for sagittal suture craniosynostosis. <i>Dev Biol</i> 2010; <b>344</b> :922-940. doi:10.1016/j.ydbio.2010.06.009
413 414 415	34.	Maruyama T, Mirando AJ, Deng C-X, Hsu W. The Balance of WNT and FGF Signaling Influences Mesenchymal Stem Cell Fate During Skeletal Development. <i>Sci Signal</i> 2010; <b>3</b> . doi:10.1126/scisignal.2000727
416 417 418	35.	Stamper BD, Park SS, Beyer RP, <i>et al.</i> Differential Expression of Extracellular Matrix- Mediated Pathways in Single-Suture Craniosynostosis. <i>PLoS One</i> 2011; <b>6</b> :e26557. doi:10.1371/journal.pone.0026557
419 420 421	36.	Çetinkaya A, Taşkıran E, Soyer T, <i>et al.</i> Dermal fibroblast transcriptome indicates contribution of wnt signaling pathways in the pathogenesis of apert syndrome. <i>Turk J Pediatr</i> 2017; <b>59</b> :619. doi:10.24953/turkjped.2017.06.001
422 423 424	37.	Rostamzad P, Arslan Z, Mathijssen I, <i>et al.</i> Prevalence of Ocular Anomalies in Craniosynostosis: A Systematic Review and Meta-Analysis. <i>J Clin Med</i> 2022; <b>11</b> :1060. doi:10.3390/jcm11041060
425 426 427	38.	Perna J, Bellato A, Ganapathy PS, <i>et al.</i> Association between Autism Spectrum Disorder (ASD) and vision problems. A systematic review and meta-analysis. <i>Mol Psychiatry</i> July 2023. doi:10.1038/s41380-023-02143-7
428 429 430	39.	Chien Y-L, Chen Y-C, Chiu Y-N, Tsai W-C, Gau SS-F. A translational exploration of the effects of <i>WNT2</i> variants on altered cortical structures in autism spectrum disorder. <i>J Psychiatry Neurosci</i> 2021; <b>46</b> :E647-E658. doi:10.1503/jpn.210022
431 432 433	40.	Yin X, Chen L, Ma M, <i>et al.</i> Altered Brain Structure and Spontaneous Functional Activity in Children With Concomitant Strabismus. <i>Front Hum Neurosci</i> 2021; <b>15</b> :777762. doi:10.3389/fnhum.2021.777762

434	41.	Bhinder MA, Sadia H, Mahmood N, et al. Consanguinity: A blessing or menace at
435		population level? Ann Hum Genet 2019;83:214-219. doi:10.1111/ahg.12308
436	42.	Khan N, Paterson AD, Roshandel D, et al. Association of IGF1 and VEGFA
437		polymorphisms with diabetic retinopathy in Pakistani population. Acta Diabetol
438		2020; <b>57</b> :237-245. doi:10.1007/s00592-019-01407-5
439	43.	Salanti G, Amountza G, Ntzani EE, Ioannidis JPA. Hardy–Weinberg equilibrium in
440		genetic association studies: an empirical evaluation of reporting, deviations, and power.
441		Eur J Hum Genet 2005;13:840-848. doi:10.1038/sj.ejhg.5201410
442	44.	Hashmi AN, Ahmed Dharejo R, Zubair U Bin, <i>et al.</i> Association of dopamine $\beta$ -
443		hydroxylase polymorphism rs1611115 and serum levels with psychiatric disorders in
444		Pakistani population. Int J Neurosci September 2022:1-9.
445		doi:10.1080/00207454.2022.2126774
446	45.	von Bartheld CS, Croes SA, Johnson LA. Strabismus. In: Levin LA, Albert DM, eds.
447		Ocular Disease: Mechanisms and Management. Philadelphia, PA: Saunders; 2010:454-
448		460.
440		

449

## 450 Acknowledgments

451 The authors thank all the participants for their contribution in the study.

# 452 Funding

This work was supported by a grant from the Higher Education Commission, Pakistan, "International Research Support Initiative" to ZZ, and a grant from the National Institutes of Health (GM103554) to CSvB and GM104944 and GM103440 to HV-G.

			Univari	able Logistic	Regressio	on Analysis		Logisti	c Regressi	on Analysis	(adjusted	for age and	gender)
SNP	Model	<sup>1</sup> OR (95%CI)	<sup>1</sup> p	<sup>2</sup> OR (95%CI)	<sup>2</sup> p	<sup>3</sup> OR (95%CI)	<sup>3</sup> p	<sup>1</sup> OR (95%CI)	<sup>1</sup> p	<sup>2</sup> OR (95%CI)	<sup>2</sup> p	<sup>3</sup> OR (95%CI)	<sup>3</sup> p
	Additive	0.94 (0.87 -	0.14	0.88 (0.80 -	0.01	0.99 (0.89 -	0.92	0.95 (0.89 -	0.21	0.92 (0.85 -	0.08	0.98 (0.88 -	0.73
rs2896218	Recessive	1.02) 1.08 (0.96 -	0.21	0.98) 1.07 (0.93 -	0.31	1.11) 1.08 (0.94 -	0.26	1.03) 1.07 (0.97 -	0.18	1.01) 1.09 (0.97 -	0.16	1.09) 1.08 (0.96 -	0.19
	Dominant	1.20) 0.75 (0.66 -	<0.01	1.23) 0.65 (0.56 -	<0.01	1.24) 0.81 (0.66 -	0.05	1.19) 0.79 (0.70 -	<0.01	$ \begin{array}{c} 1.23) \\ 0.71 \\ (0.62 - 0.82) \end{array} $	<0.01	1.24) 0.76 (0.62 -	<0.01
	Additive	1.12 (0.97 -	0.12	1.09 (0.94 -	0.27	1.11 (0.96 -	0.17	1.02 (0.91 -	0.72	1.00 (0.87 -	0.94	1.02 (0.88 -	0.81
rs3779550	Recessive	1.28) 0.82 (0.55 -	0.35	1.26) 0.89 (0.59 -	0.50	1.29) 0.84 (0.55 -	0.43	1.16) 0.92 (0.63 -	0.64	1.15) 0.94 (0.63 -	0.76	1.18) 0.89 (0.58 -	0.59
	Dominant	1.23) 1.17 (1.00 -	0.04	1.34) 1.12 (0.96 -	0.15	1.29) 1.16 (0.99 -	0.07	1.33) 1.04 (0.91 -	0.58	1.40) 1.01 (0.87 -	0.85	1.36) 1.04 (0.89 -	0.64
	Additive	1.36) 0.92 (0.85 -	0.06	1.32) 0.90 (0.81-	0.04	1.37) 0.93 (0.85 -	0.17	1.19) 0.94 (0.87 -	0.10	1.18) 0.95 (0.87 -	0.20	1.21) 0.93 (0.85 -	0.12
rs2285544	Recessive	1.00) 1.31 (0.96 -	0.09	0.99) 1.17 (0.73 -	0.50	1.03) 1.43 (0.99 -	0.05	1.01) 1.10 (0.83 -	0.49	1.03) 1.09 (0.73 -	0.69	1.02) 1.21 (0.87 -	0.26
	Dominant	1.79 0.89 (0.81 - 0.97)	0.01	1.87) 0.88 (0.79 - 0.98)	0.02	2.05) 0.89 (0.81 - 0.99)	0.04	(0.85 - 0.99)	0.05	1.62) 0.94 (0.85 - 1.03)	0.16	1.68) 0.90 (0.82 - 0.99)	0.04
rs4730775	Additive	1.10 (1.00 - 1.21)	0.05	1.08 (0.95 - 1.22)	0.22	1.14 (1.01 - 1.28)	0.03	1.07 (0.99 - 1.16)	0.08	1.05 (0.95 - 1.16)	0.34	1.14 (1.03 - 1.26)	0.01
101700770	Recessive	1.14 (0.94 - 1.38)	0.19	1.09 (0.84 - 1.41)	0.52	1.22 (0.96 - 1.54)	0.10	1.07 (0.91 - 1.25)	0.43	1.08 (0.88 - 1.33)	0.48	1.17 (0.95 - 1.44)	0.13

456 Table 1: Logistic regression analysis results for the studied variants. Statistically significant p-values are indicated in bold font.

	Dominant	1.15	0.05	1.13	0.19	1.19	0.05	1.13	0.05	1.07	0.38	1.22	0.01
		(1.00-		(0.94 -		(1.00 -		(1.00 -		(0.92 -		(1.04 -	
		1.33)		1.35)		1.43)		1.27)		1.24)		1.42)	
	Additive	1.10	0.06	1.08	0.24	1.14	0.04	1.06	0.15	1.04	0.47	1.11	0.06
		(0.99 -		(0.95 -		(1.00 -		(0.98 -		(0.94 -		(0.99 -	
		1.21)		1.22)		1.28)		1.16)		1.15)		1.23)	
	Recessive	1.15	0.15	1.14	0.31	1.20	0.13	1.06	0.46	1.09	0.39	1.10	0.39
rs3840660		(0.95 -		(0.89 -		(0.95 -		(0.90 -		(0.89 -		(0.89 -	
		1.39)		1.46)		1.53)		1.25)		1.34)		1.36)	
	Dominant	1.13	0.10	1.09	0.34	1.18	0.07	1.10	0.13	1.03	0.68	1.18	0.04
		(0.98 -		(0.91 -		(0.99 -		(0.97 -		(0.89 -		(1.01 -	
		1.31)		1.31)		1.42)		1.25)		1.20)		1.38)	
	Additive	0.97	0.56	0.97	0.66	0.97	0.58	0.97	0.42	0.94	0.30	0.97	0.54
		(0.88 -		(0.86 -		(0.86 -		(0.89 -		(0.86 -		(0.87 -	
		1.07)		1.09)		1.09)		1.04)		1.04)		1.07)	
	Recessive	0.98	0.78	0.96	0.70	0.99	0.93	0.97	0.62	0.93	0.41	0.99	0.94
rs2024233		(0.83 -		(0.78 -		(0.81 -		(0.84 -		(0.79 -		(0.83 -	
		1.15)		1.18)		1.21)		1.11)		1.10)		1.19)	
	Dominant	0.95	0.50	0.97	0.74	0.92	0.41	0.95	0.40	0.93	0.37	0.92	0.35
		(0.81 -		(0.79 -		(0.76 -		(0.83 -		(0.79 -		(0.78 -	
		1.11)		1.18)		1.12)		1.08)		1.09)		1.09)	

457 <sup>1</sup>Strabismus vs Controls, <sup>2</sup>Esotropia vs Controls, <sup>3</sup>Exotropia vs Controls

		Strabisn	nus Diagnose	ed at Birth	n vs Control		Strabismus Diagnosed Later vs Control						
SNP	<sup>1</sup> OR (95%CI)	<sup>1</sup> p	<sup>2</sup> OR (95%CI)	<sup>2</sup> p	<sup>3</sup> OR (95%CI)	<sup>3</sup> p	<sup>1</sup> OR (95%CI)	<sup>1</sup> p	<sup>2</sup> OR (95%CI)	<sup>2</sup> p	<sup>3</sup> OR (95%CI)	<sup>3</sup> p	
rs2896218	0.83 (0.73 - 0.94)	<0.01	0.84 (0.76 - 0.92)	<0.01	0.93 (0.82 - 1.05)	0.23	0.97 (0.86 - 1.09)	0.63	0.94 (0.85 - 1.03)	0.19	1.07 (0.97 - 1.17)	0.21	
rs3779550	1.13 (0.98 - 1.31)	0.08	0.99 (0.89 - 1.10)	0.96	1.09 (0.96 - 1.26)	0.19	1.07 (0.92 - 1.23)	0.39	1.05 (0.93 - 1.18)	0.42	1.01 (0.91 - 1.14)	0.80	
rs2285544	0.89 (0.81 - 0.99)	0.04	0.95 (0.88 - 1.03)	0.21	0.91 (0.83 - 1.00)	0.06	0.93 (0.83 - 1.03)	0.15	0.92 (0.85 - 1.00)	0.05	1.03 (0.95 - 1.11)	0.51	
rs4730775	1.14 (1.00 - 1.30)	0.05	1.15 (1.02 - 1.31)	0.03	1.06 (0.93 - 1.21)	0.38	0.97 (0.85 - 1.11)	0.69	1.02 (0.90 - 1.14)	0.80	0.93 (0.84 - 1.04)	0.22	
rs3840660	1.13 (0.98 - 1.29)	0.09	1.11 (0.98 - 1.26)	0.11	1.08 (0.94 - 1.23)	0.28	0.99 (0.87 - 1.13)	0.95	1.02 (0.90- 1.15)	0.80	0.97 (0.87 - 1.08)	0.59	
rs2024233	0.96 (0.85 - 1.09)	0.57	0.94 (0.83 - 1.05)	0.28	1.01 (0.89 - 1.14)	0.94	1.09 (0.97 - 1.22)	0.16	1.05 (0.94 - 1.18)	0.36	1.07 (0.97 - 1.17)	0.17	
rs2244352	0.98 (0.90 - 1.07)	0.67	0.99 - 0.93) (1.07	0.99	0.98 (0.91 - 1.07)	0.69	1.03 (0.95 1.12)	0.45	1.02 (0.96 - 1.09)	0.52	1.02 (0.96 - 1.09)	0.46	

Table 2: Univariate regression for strabismus diagnosed at birth and diagnosed later when compared to controls separately (Additive
 model). Statistically significant p-values are indicated in bold font.

461 <sup>1</sup> Strabismus vs Controls, <sup>2</sup> Esotropia vs Controls, <sup>3</sup> Exotropia vs Controls

	Stra	abismus wi	ith Positive <b>1</b>	Family Hi	story vs Con	trols	Strabismus with No Family History vs Controls						
SNP	<sup>1</sup> OR (95%CI)	<sup>1</sup> p	<sup>2</sup> OR (95%CI)	<sup>2</sup> p	<sup>3</sup> OR (95%CI)	<sup>3</sup> p	<sup>1</sup> OR (95%CI)	<sup>1</sup> p	<sup>2</sup> OR (95%CI)	<sup>2</sup> p	<sup>3</sup> OR (95%CI)	<sup>3</sup> p	
rs2896218	0.88 (0.79 - 0.97)	0.01	0.85 (0.77 - 0.94)	<0.01	0.96 (0.87 - 1.07)	0.50	0.98 (0.88 - 1.09)	0.68	0.92 (0.84 - 1.02)	0.11	1.04 (0.93 - 1.17)	0.46	
rs3779550	1.04 (0.90 - 1.19)	0.60	1.00 (0.89 - 1.12)	0.99	1.07 (0.95 - 1.20)	0.28	1.16 (0.99 - 1.36)	0.05	1.09 (0.96 - 1.23)	0.17	1.10 (0.96 - 1.26)	0.17	
rs2285544	0.89 (0.82 - 0.99)	0.03	$0.89 \\ (0.82 - 0.98)$	0.01	0.97 (0.89 - 1.04)	0.42	0.93 (0.84 - 1.03)	0.15	0.95 (0.88 - 1.04)	0.26	0.96 (0.87 - 1.05)	0.34	
rs4730775	1.13 (0.99 - 1.29)	0.06	1.06 (0.94 - 1.21)	0.34	1.14 (1.01 - 1.29)	0.03	1.03 (0.90 - 1.17)	0.71	1.06 (0.94 - 1.20)	0.34	0.98 (0.86 - 1.11)	0.71	
rs3840660	1.16 (1.02 - 1.32)	0.02	1.09 (0.97 - 1.23)	0.16	1.15 (1.02 - 1.30)	0.02	0.98 (0.86 - 1.13)	0.80	0.98 (0.87 - 1.12)	0.80	0.99 (0.87 - 1.13)	0.89	
rs2024233	0.91 (0.81 - 1.03)	0.14	0.92 (0.82 - 1.03)	0.15	0.95 (0.84 - 1.07)	0.42	1.10 (0.97 - 1.25)	0.12	1.10 (0.97 - 1.23)	0.13	1.05 (0.94 - 1.19)	0.38	
rs2244352	0.98 (0.90 - 1.07)	0.68	0.99 (0.92 - 1.07)	0.81	1.00 (0.93 - 1.08)	0.97	1.02 (0.94 - 1.11)	0.60	1.02 (0.96 - 1.10)	0.51	1.01 (0.93 - 1.09)	0.87	

Table 3: Univariate regression for strabismus cases with positive family history and no family history when compared to controls
 separately (Additive model). Statistically significant p-values are indicated in bold font.

465 <sup>1</sup> Strabismus vs Controls, <sup>2</sup> Esotropia vs Controls, <sup>3</sup> Exotropia vs Controls

	Stra	bismus wi	th Consangu	iineous Pa	arents vs Cor	ntrols	Strabismus with Non-Consanguineous Parents vs Controls						
SNP	<sup>1</sup> OR (95%CI)	<sup>1</sup> p	<sup>2</sup> OR (95%CI)	<sup>2</sup> p	<sup>3</sup> OR (95%CI)	<sup>3</sup> p	<sup>1</sup> OR (95%CI)	<sup>1</sup> p	<sup>2</sup> OR (95%CI)	<sup>2</sup> p	<sup>3</sup> OR (95%CI)	<sup>3</sup> p	
rs2896218	0.94 (0.85 - 1.04)	0.25	0.87 (0.79 - 0.96)	<0.01	1.03 (0.92 - 1.14)	0.66	0.90 (0.80 - 1.00)	0.05	0.90 (0.81 - 0.99)	0.02	0.97 (0.87 - 1.07)	0.53	
rs3779550	0.95 (0.86 - 1.05)	0.35	1.01 (0.89 - 1.15)	0.84	1.11 (0.96 - 1.28)	0.15	1.15 (1.00 - 1.33)	0.04	1.06 (0.95 - 1.18)	0.31	1.11 (0.99 - 1.25)	0.08	
rs2285544	1.07 (0.93 - 1.24)	0.34	0.94 (0.85 - 1.02)	0.15	0.99 (0.90 - 1.09)	0.91	0.93 (0.84 - 1.02)	0.13	0.98 (0.90 - 1.06)	0.55	0.94 (0.87 - 1.02)	0.12	
rs4730775	1.09 (0.96 - 1.23)	0.17	1.12 (0.99 - 1.27)	0.06	1.03 (0.91 - 1.18)	0.63	1.11 (0.97 - 1.26)	0.13	1.04 (0.91 - 1.18)	0.55	1.12 (0.99 - 1.27)	0.07	
rs3840660	1.10 (0.97 - 1.24)	0.12	1.15 (1.02 - 1.29)	0.03	1.02 (0.90 - 1.17)	0.73	1.08 (0.94 - 1.24)	0.26	1.00 (0.88 - 1.14)	0.98	1.13 (1.00 - 1.28)	0.06	
rs2024233	0.90 (0.80 - 1.01)	0.08	0.87 (0.77 - 0.98)	0.02	0.97 (0.86 - 1.09)	0.58	1.12 (0.99 - 1.28)	0.07	1.11 (0.99 - 1.25)	0.09	1.06 (0.95 - 1.19)	0.32	
rs2244352	0.99 (0.91 - 1.07)	0.77	0.99 (0.92 - 1.08)	0.95	0.99 (0.92 - 1.08)	0.94	1.02 (0.94 - 1.11)	0.66	1.02 (0.95 - 1.09)	0.58	1.00 (0.93 - 1.08)	0.94	

Table 4: Univariate regression for strabismus cases whose parents had a consanguineous marriage and those with non-consanguineous
 marriage when compared to controls separately (Additive model). Statistically significant p-values are indicated in bold font.

469 <sup>1</sup> Strabismus vs Controls, <sup>2</sup> Esotropia vs Controls, <sup>3</sup> Exotropia vs Controls

471 Table 5: Univariate regression for strabismus cases who had intrauterine or early infancy exposure to cigarette smoke and those with

472 no smoking exposure when compared to controls separately (Additive model). Statistically significant p-values are indicated in bold

473 font.

	S	trabismu	s with Smoki	ng Exposi	ure vs Contro	ols	Str	Strabismus with No Smoking Exposure vs Controls							
SNP	<sup>1</sup> OR (95%CI)	<sup>1</sup> p	<sup>2</sup> OR (95%CI)	<sup>2</sup> p	<sup>3</sup> OR (95%CI)	<sup>3</sup> p	<sup>1</sup> OR (95%CI)	<sup>1</sup> p	<sup>2</sup> OR (95%CI)	²p	<sup>3</sup> OR (95%CI)	<sup>3</sup> p			
rs2896218	0.92 (0.83 - 1.03)	0.14	0.92 (0.85 - 1.00)	0.06	0.97 (0.88 - 1.08)	0.60	0.95 (0.86 - 1.06)	0.36	0.91 (0.82 - 1.00)	0.06	1.02 (0.91 - 1.14)	0.74			
rs3779550	1.07 (0.94 - 1.22)	0.30	1.01 (0.92 - 1.11)	0.83	1.07 (0.96 - 1.20)	0.24	1.09 (0.94 - 1.26)	0.24	1.04 (0.92 - 1.17)	0.55	1.11 (0.96 - 1.27)	0.15			
rs2285544	0.96 (0.88- 1.05)	0.33	0.97 (0.91 - 1.04)	0.41	0.97 (0.90 - 1.05)	0.42	0.90 (0.81 - 0.99)	0.03	0.96 (0.88 - 1.05)	0.35	0.91 (0.83 - 0.99)	0.05			
rs4730775	1.12 (0.98 - 1.28)	0.08	1.11 (0.99 - 1.24)	0.07	1.05 (0.93 - 1.19)	0.42	0.99 (0.87- 1.13)	0.90	1.01 (0.88 - 1.15)	0.91	0.98 (0.86 - 1.11)	0.72			
rs3840660	1.08 (0.95 - 1.24)	0.25	1.05 (0.93 - 1.17)	0.43	1.06 (0.94 - 1.19)	0.36	1.04 (0.91 - 1.18)	0.61	1.03 (0.91 - 1.18)	0.60	1.02 (0.90 - 1.15)	0.79			
rs2024233	1.03 (0.92 - 1.17)	0.59	1.02 (0.92 - 1.14)	0.67	1.02 (0.92 - 1.14)	0.68	1.01 (0.89 - 1.14)	0.92	1.00 (0.89 - 1.13)	0.94	1.00 (0.90 - 1.13)	0.94			
rs2244352	1.01 (0.93 - 1.09)	0.85	1.02 (0.97 - 1.08)	0.38	0.99 (0.93 - 1.06)	0.84	1.02 (0.94- 1.11)	0.69	1.03 (0.96 - 1.11)	0.41	1.00 (0.93- 1.08)	0.99			

474 <sup>1</sup> Strabismus vs Controls, <sup>2</sup> Esotropia vs Controls, <sup>3</sup> Exotropia vs Controls

Rs2896218	Rs3779550	Rs2285544	In Total (n=291)	In Controls (n=155)	In Strabismus (n=136)	OR (95% CI)	P-value
			number	Number	Number		
			(frequency)	(frequency)	(frequency)		
G	Т	Т	137 (0.24)	77 (0.25)	60 (0.22)	0.86 (0.58 -	0.43
						1.26)	
G	C	Т	110 (0.19)	66 (0.21)	44 (0.16)	0.71 (0.47 -	0.14
						1.09)	
Α	Т	Т	86 (0.15)	32 (0.10)	54 (0.20)	2.15 (1.34 -	<0.01
						3.45)	
Α	С	A	78 (0.13)	50 (0.16)	28 (0.10)	0.60 (0.36 -	0.05
						0.98)	
Α	C	Т	71 (0.12)	32 (0.10)	39 (0.14)	1.45 (0.88 -	0.16
						2.39)	
G	C	A	59 (0.10)	24 (0.08)	35 (0.13)	1.76 (1.02 -	0.05
						3.04)	
Α	Т	A	37 (0.06)	28 (0.09)	9 (0.03)	0.35 (0.16 -	<0.01
						0.74)	
G	Т	А	4 (7.00e-03)	1 (3.00e-03)	3 (0.01)	3.45 (0.36 -	0.34
						33.36)	

476 Table 6: Distribution of haplotypes in strabismus and control groups. Statistically significant p-values are indicated in bold font.

477 CI, confidence interval; OR, odds ratio; n, number of samples analyzed

Supplementary Figure 1: Graphical representation of principal component 1 (PC1) plotted
against principal component 2 (PC2) after PCA analysis showing a separate cluster for our
strabismus cohort (labeled as EXP.STB), while no stratification is observed for our control
cohort (labeled as EXP.CTR) with 1000 Genomes data.



482

AFR, Africans; AMR, Native Americans; EAS, East Asians; EUR, Europeans; EXP.CTR, Experimental Controls;
 EXP.STB, Experimental Strabismus; SAS, South Asians.

SNPs	Primers (5' – 3')	Annealing	Product Length	
		Temperature	(bp)	
WNT2				
	OF – CACAGATGATCACTATTGCCACTTA	60.4°C	OE OB = 617	
DC2006210	OR – AATCATTCTGACCAAACGCTG	58.7°C	OF - OK = 017	
K52090210	IF – GTCTTCCTTTTGATATCTCTGCCG	62.5°C	VF - IR = 408 IF $OR = 102$	
	IR – GAGAGACAGTCACGAGGCCTT	61.0°C	II - OK - 193	
	OF – CTGCTCGTCACTTCTCCTCA	59.3°C	OE OB = 512	
DC2205544	OR – GCTGCTGAGTGCTGAACAAG	59.9°C	OF - OR = 313	
K82285544	IF – CACAGGCTTTTGGCTTCTCAT	61.7°C	OF - IR = 332 IF OP = 201	
	IR – CAGACTTCCCATCTGCACCT	60.3°C	$- \Pi - OK - 201$	
RS3779550	OF – CTGTCCCACTGAGGTGACTT	57.7°C	OF OD 207	
	OR – CAATGCAGCAGATGAGAGTAAC	57.7°C	OF - OR = 38 / OF - OR = 07	
	IF – AGCCAAGGTCGTGCAAC	58.3°C	$\frac{\text{OF-IK} - 9}{\text{IE OP} - 366}$	
	IR – CGCCCAGGCTGGAGTATAA	61.1°C	$11^{-}OK = 300$	
3'UTR region	F – CAGTATCACATCATCTTGTAAGCATC	59.1°C	070	
	R – CTCAAAGGAGCTTTCTCAATGTC	59.5°C	020	

485	Supplementary	y Table 1: Sec	juences and	details of the	primers us	ed in the	present study

486 Bp, base pairs; F, Forward Primer; IF, Inner Forward Primer; IR, Inner Reverse Primer; OF, Outer Forward Primer;

487 OR, Outer Reverse Primer; R, Reverse Primer; 3'UTR, 3'untranslated region

Subjects	Controls	Strabismus	Esotropia	Exotropia
Total (N)	230	315	141	162
Gender (Male) (%)	64.25	52.90	52.48	53.70
Age (Years) (mean (±SD))*	28.21 (±12.39)	16.39 (±9.10)	14.27 (±8.77)	18.11 (±9.08)
Diagnosed at Birth	NA	52.10	40.74	60.74
(Congenital) (%)				
Positive family history (%)	NA	50.88	55.55	47.58
Parental Consanguinity (%)	NA	67.08	63.46	69.70

# 488 **Supplementary Table 2**: Demographic details of the examined cohorts

489 Values are N for total, percentage (%) for gender and diagnosed at birth, Mean (SD) for age, NA, not applicable.

490 \*Limitation: Most of the strabismus patients were young children (below the age of 10), but we could not obtain

491 approval of guardians to sample an equal number of unaffected children, thus we used older individuals (ages >14).

492	Supplementary Table 3: Distribution of allele frequencies among the control and disease group along with the calculated a	and
493	reported minor allele frequencies (MAFs).	

RS Number	Ancestral allele	Risk allele	A1 frequency		A2 frequency		MAF <sup>1</sup>	MAF <sup>2</sup>	MAF <sup>3</sup>	$\chi^2$ (p-	$\chi^2$ (p-
	(A1)	(A2)	Control (n (%))	<b>Disease</b> (n (%))	<b>Control</b> (n (%))	<b>Disease</b> (n (%))				value)	value) <sup>3</sup>
Rs2896218	A	G	197 (44.97%)	296 (48.37%)	241 (55.02%)	316 (51.63%)	0.45(A)	0.48 (A)	0.62 (A)*	12.27 (< <b>0.01</b> )	8.32 (<0.01)
Rs3779550	С	Т	236 (55.92%)	248 (53.45%)	186 (44.07%)	216 (46.55%)	0.44 (T)	0.46 (T)	0.32 (T)	6.62 (0.01)	9.01 (< <b>0.01</b> )
Rs2285544	Т	A	295 (69.57%)	361 (74.27%)	129 (30.42%)	125 (25.72%)	0.30 (A)	0.26 (A)	0.39 (A)	3.41 (0.06)	7.10 (< <b>0.01</b> )
rs4730775	C	Т	90 (71.43%)	127 (59.90%)	36 (28.57%)	85 (40.10%)	0.29 (T)	0.40 (T)	0.32 (T)	0.41 (0.52)	2.94 (0.09)
rs3840660	No ins	insA	90 (68.18%)	122 (57.55%)	42 (31.82%)	90 (42.45%)	0.32 (A)	0.42 (A)	0.34 (A)	0.18 (0.67)	2.85 (0.09)
rs2024233	А	G	66 (50.77%)	114 (54.29%)	64 (49.23%)	96 (45.71%)	0.49 (G)	0.46 (G)	0.37 (G)	6.18 (0.01)	3.48 (0.06)

494 <sup>1</sup>MAF calculated from control cohort of present study

495 <sup>2</sup>MAF calculated from disease cohort

496 <sup>3</sup>MAF reported for PJL from Ensembl (https://asia.ensembl.org/Homo\_sapiens/Info/Index)

497 <sup>4</sup>Chi-square results for controls and reported data (PJL from Ensembl)

498 <sup>5</sup>Chi-square results for disease and reported data (PJL from Ensembl)

499 \* The frequency of A allele was calculated from MAF (G) reported inPJL for rs2896218

500 Significant p-values (<0.05) are shown in bold font

501 ins stands for insertion, insA is insertion of A nucleotide

502 n, number of alleles

	rs2896218	rs3779550	rs2285544	rs4730775	rs3840660
rs3779550	D': 0.87				
	$R^2: 0.82$				
	Chi-sq: 72.34				
	p-value: <0.01				
rs2285544	D': 0.85	D': 0.70			
	$R^2: 0.76$	$R^2: 0.66$			
	Chi-sq: 61.79	Chi-sq: 47.26			
	p-value: <b>&lt;0.01</b>	p-value: <0.01			
rs4730775	D': 0.19	D': 0.11	D': 0.08		
	$R^2: 0.13$	$R^2: 0.08$	$R^2: 0.06$		
	Chi-sq: 1.69	Chi-sq: 0.66	Chi-sq: 0.40		
	p-value: 0.19	p-value: 0.42	p-value: 0.53		
rs3840660	D': 0.36	D': 0.08	D': 0.07	D': 0.85	
	$R^2: 0.25$	$R^2: 0.06$	$R^2: 0.05$	$R^2: 0.79$	
	Chi-sq: 6.93	Chi-sq: 0.44	Chi-sq: 0.28	Chi-sq: 68.10	
	p-value: <b>&lt;0.01</b>	p-value: 0.51	p-value: 0.60	p-value: <b>&lt;0.01</b>	
rs2024233	D': 0.24	D': 0.14	D': 0.31	D': 0.39	D': 0.59
	$R^2$ : -0.13	$R^2: 0.13$	$R^2: 0.27$	$R^2$ : -0.24	$R^2$ : -0.38
	Chi-sq: 5.02	Chi-sq: 1.73	Chi-sq: 7.85	Chi-sq: 6.02	Chi-sq: 15.36
	p-value: <b>0.02</b>	p-value: 0.19	p-value: <b>&lt;0.01</b>	p-value: 0.01	p-value: <b>&lt;0.01</b>

**Supplementary Table 4:** Linkage disequilibrium matrix showing D',  $R^2$ , chi square and p-values for the studied variants for the 504 control cohort. Statistically significant p-values are indicated in bold font.